Texas Children’s Cancer Center is the country’s leader in the use of precision oncology strategies for the care of children with rare, relapsed, refractory and high-risk cancers – patients with limited treatment options who are most in need of novel therapeutic approaches.
Our precision oncology team applies state-of-the-art genomic testing to make the most informed decisions possible for the care of each child evaluated and treated at Texas Children’s Cancer Center.
Researchers in the Cancer Genetics and Genomics Program are leading cutting-edge studies to understand how genome sequencing can be used to implement more precisely-targeted patient-specific treatment plans and improve outcomes for childhood cancer patients.
The multidisciplinary precision oncology team at Texas Children’s Cancer Center comprises experts in personalized medicine including oncologists, pathologists, surgeons, and geneticists who work together to identify the best treatment and clinical trial options for each individual patient. Importantly, this team has expertise in the genetics and treatment of each type of childhood cancer and extensive experience with the development and evaluation of innovative new cancer therapies.